A Study of the Use of Varenicline to Treat Smoking Addiction in Patients with Alcoholism

Overview

About this study

The purpose of this study is to see if varenicline will decrease alcohol consumption and increase alcohol abstinence rates when given to alcoholic patients for both alcohol and smoking cesation treatment.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria

  • Age > 18 and < 70 years
  • Admitted to the inpatient addiction program (IAP) in the Generose Building at Saint Marys Hospital
  • Diagnosed with alcohol dependence based on DSM-IV-TR criteria and confirmed by Psychiatric Research Interview for Substance and Mental Disorders (PRISM)
  • Has smoked at least 10 cigarettes/day for ≥ 6 months
  • Able to participate fully in all aspects of the study
  • Has been provided with, understands, and has signed the informed consent
  • Agrees to identify collateral individuals for contact purposes to facilitate follow-up appointments

Exclusion Criteria

  • Meets DSM-IV criteria of schizophrenia or other non-affective psychotic disorder
  • Has had psychotic symptoms within the past month
  • Has an Axis I disorder requiring new pharmacotherapy
  • Has a predominant Axis II disorder
  • Has used an investigational drug within 30 days of enrollment
  • Has started Naltrexone or Acamprosate during this same IAP admission
  • Has a history (past 3 months) of drug abuse (excluding caffeine and marijuana)
  • Has active suicidality as measured by screening questions from the Columbia-Suicide Severity Rating Scale (C-SSRS)(Posner 2008)
    • "Yes" response to questions 1, 2, or 3 with significant intensity level endorsed as
      • Frequency score of 4 or 5 
      • Duration score of 3, 4 or 5
      • Controllability score of 0, 4, or 5
      • Deterrents score of 0, 4 or 5
      • Reasons for Ideation score of 1, 2, 3, 4 or 5
    • "Yes" response to question 4 c
    • "Yes" response to question 5
  • History of medically serious suicide attempt within 5 years
  • History of any major cardiovascular events including arrhythmias, congestive heart failure, unstable angina, acute MI or coronary angioplasty
  • Pregnant or lactating
  • Of child bearing potential, likely to become pregnant during the medication phase and not willing to use a reliable form of contraception
    • Reliable forms of contraception include diaphragm or condom (with spermicidal), injections, intrauterine device [IUD], surgical sterilization and abstinence
  • Has clinically significant acute or chronic progressive or unstable neurologic, hepatic, renal, cardiovascular, respiratory or metabolic disease
  • Has another household member or relative participating in the study
  • Has a known allergy to varenicline
  • In the investigators opinion, unable to comply with study procedures
  • Unable to provide written informed consent in English
  • On hemodialysis or has a history of kidney disease
  • Cannot participate in the MR spectroscopy because of 
    • Claustrophobia
    • A history of major head trauma with loss of consciousness > 5 minutes or skull fracture
    • A history of previous neurological event (e.g., epilepsy, stroke, transient ischemic attack)
    • Implanted metal objects (e.g., pacemakers; aneurysm clips; metal prostheses, joints, rods, or plates)
    • Other contraindication to MRI scanning

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Mark Frye, M.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20312637

Mayo Clinic Footer